- News
- Galenicum Health, now in Colombia
- Galenicum Health obtains approval for Anastrozole in Brazil
- GSI USA participates in the Probiota Americas congress
- Good news for generics companies: European Commission refines intellectual property rules
- We inaugurated the new Galenicum's Office in Peru
- Galenicum Health is getting prepared for the upcoming pharmaceutical events of 2018
- Galenicum Special Ingredients makes The Financial Times 1000 List of Europe's Fastest Growing Companies in 2018
- Galenicum's new team in Colombia
- Galenicum Health assists to the DCAT Week in New York
- Galenicum Health in the peruvian news
- Galenicum Special Ingredients participates in Food Ingredients China
- Galenicum Health Peru launches its first OTC product
- Galenicum Health submits the dossier for Paracetamol in Spain
- Galenicum Health to launch in Southeast Asia
- Galenicum Health Peru will launch the food supplement line STOP&GO
- Galenicum Health Peru and the Dominican Republic are launching dexketoprofen
- Galenicum Health obtains the bioequivalence studies for Sitagliptin/Metformin combination
- GSI will attend the Nutraceuticals Europe Summit & Expo 2018 in Madrid
- Silanes and Galenicum Health launch dexketoprofen in Mexico
- Galenicum Health Peru and Chile launch a new business unit focused on pain relief with dexketoprofen and celecoxib
- Galenicum obtains the approval of the DCP of Anagrelide
- GSI attends the FI Europe 2017 in Frankfurt
- Galenicum participates in the 8th Edition of ESADE Innovation Quest
- FDA takes unprecedented step toward more efficient global pharmaceutical manufacturing inspections
- Galenicum enters agreement with Optibiotix to commercialise LPLDL® strain
- Galenicum will top €100 million in sales for the first time ever this year
- Galenicum attends the CPhI Worldwide 2017 in Frankfurt
- World International Day against Breast Cancer
- World Mental Health Day 2017: MENTAL HEALTH IN THE WORKPLACE
- GSI EEUU participates in Supply Side West 2017
- World Alzheimer's Day
- Galenicum Health Peru launches new intensive care business unit
- Galenicum launches Dutasteride in the European Market
- World Hepatitis Day
- Galenicum obtains DCP approval for Tigecycline
- Galenicum launches the new food supplement brand STOP&GO in Spanish pharmacies
- The importance of bioequivalence studies explained on Peruvian radio
- Galenicum obtains approval for first injectable product
- Galenicum launches in the Dominican Republic
- Galenicum at CPhI 2016
- The experiences of Sofía and Gabriel in the Hospital without Pain
- Galenicum, awarded for entrepreneurial trajectory
- Hospital without Pain. Story of Cristina, Victor’s mother.
- Share life, give blood
- SAG manufacturing has been certified by ANVISA
- Galenicum organizes the 3rd Workshop of Alzheimer Disease
- The success of Galenicum Health Peru in the last cardiology event of the country
- The bioequivalent medicines of Galenicum Health are already available in the main cities of Peru
- Galenicum with the World Health Day
- 3rth edition of University Joins Industry, once again a success
- Once again Galenicum as one of the companies with more patent submissions
- Biosimilar products, the challenge of the XXI century
- Galenicum in the news
- Past and future of Galenicum Health Peru
- Galenicum and Hospital Sant Joan de Déu making children’s life easier
- Galenicum challenges ESADE students
- Galenicum participates in the conference “Destination Peru, country of opportunities”
- Galenicum breaks new ground at the CPhI
- Generic drugs stand now for a 40% of the total pharmaceutical market in Spain
- The AEMPS boosts bioequivalence in Latin America through training
- Bioequivalent drugs, one of Peru’s main goals for the next year
- The false myths about generic medicines
- Galenicum, one step ahead of the generics
- Galenicum bring us closer to the generics world
- Galenicum and Parc Sanitari Sant Joan de Déu launch an innovative health guide
- GSI towards a new horizon
- The Peruvian Doctors Association reflects the need of implementing the bioequivalence studies as a measure of safety and effectiveness of generic drugs
- Galenicum, referent company on bioequivalent drugs, on Peruvian TV
- Galenicum Chile presents its portfolio of products
- Galenicum Perú presents its first product launches on “Mundo Empresarial”
- Galenicum analyses the challenges of the supply chain in the Forum ETSEIB 2015
- Galenicum and UB promote the second edition of “University Joins Industry”
- Galenicum, second Spanish pharmaceutical company in patent applications in 2014
- Galenicum introduces bioequivalent drugs in Peru
- Galenicum receives a visit from Xavier Trias, Mayor of Barcelona
- Galenicum, guest of honor at the Spain National Champions reception of the European Business Awards 2014/15
- Galenicum advances in developing its product pipeline
- Galenicum attended CPhI Worldwide 2014 in Paris
- Galenicum challenges the participants in the ESADE Innovation Quest 2014
- Galenicum, Business of the Year in the European Business Awards 2013/14
- Galenicum profiles its first launches for 2014
- Galenicum participates in the ETSEIB Forum 2014
- Galenicum and Uriach introduce Cilostazol in Sweden and UK
- Galenicum shortlisted in top 100 at European Business Awards 2013/14
- Sant Joan de Déu Barcelona Children’s Hospital and Galenicum join forces against child pain
- Galenicum shows its commitment to training by participating in University Joins Industry
- Galenicum attended CPhI Worlwide 2013 in Frankfurt
- Galenicum participates in the ESADE Innovation Quest 2013
- Galenicum among the National Champions of the European Business Awards 2013/14
- Galenicum hosts first edition of Innovation Awards
- Galenicum submits dossier for Almotriptan in several European countries
- Galenicum gets Marketing Authorizations for Dexketoprofen sachets in Spain
- Galenicum grows with a view to internationalisation
- Galenicum and Laboratorios Rubió sign a distribution agreement for Rubifen in Peru
- Galenicum opens new offices in Peru
- Galenicum announces successful bioequivalence study for Dutasteride
- Galenicum celebrates the yearly cocktail at CPhI
- Galenicum at CPhI Worldwide 2012
- Galenicum enters the Brazil market
- Galenicum presents its Strategy Board
- Galenicum attends the EuroPLX 45 in Portugal
- Qc LAB extensions passes GMP inspection
- Positive outcome of CPhi
- New investments in the lab for Quality Control for our customers
News
Galenicum Health Peru and Chile launch a new business unit focused on pain relief with dexketoprofen and celecoxib
January 26, 2018
Galenicum Health Peru and Galenicum Health Chile are launching this year a new business unit focused on products for pain relief. This are dexketoprofen for Peru and celecoxib for Chile. Both are nonsteroidal anti-inflammatory drugs, indicated to reduce inflammation and relieve pain.
These products suit perfectly our growing portfolio in the cardiovascular, neuroscience and oncology therapeutic areas.
We hope to achieve a great reception in both countries and help patients and doctors to obtain a new safe and effective therapeutic option.
